Skip to main
AORT

Artivion (AORT) Stock Forecast & Price Target

Artivion (AORT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Artivion is a global leader in the field of cardiovascular medical devices and technology, with a strong focus on aortic-centric solutions. The company's diverse portfolio of products, including aortic and mitral heart valves, allografts and patches, and surgical adhesives, has a wide reach in North America, EMEA, LATAM, and APAC. The company's recent PMA approvals and ongoing pipeline of products, including Arcevo and NEXUS, position it for long-term growth in the 10%-14% range. Despite recent challenges with the rollout of AMDS, management believes it is an air pocket and not a structural issue, and they are taking steps to overcome barriers to adoption. With a strong backlog of new accounts waiting to issue purchase orders and potential solutions to ease upfront costs, Artivion's revenue is poised to rebound. Additionally, the company is making strategic acquisitions, such as Endospan and Ascyrus Medical, to further expand its product offerings and drive future growth. Overall, Artivion's strong financials, with a 19.0% adjusted EBITDA margin and plans for debt reduction through use of FCF, make it a promising investment opportunity for the long-term.

Bears say

Artivion is facing several challenges that could have a negative impact on its financial performance and stock price. These include potential disruptions and delays in the adoption of its new products, which could adversely affect its bottom line and market share. Additionally, the company faces competition from larger and more established players in the MedTech industry, as well as regulatory and environmental risks related to its product portfolio and operations. The company's dependence on its preservation services segment also poses a risk, as it is subject to potential uncertainties in donor volume, donation quality, and fluctuations in demand.

Artivion (AORT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artivion (AORT) Forecast

Analysts have given Artivion (AORT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Artivion (AORT) has a Strong Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artivion (AORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.